title: 30-day intravenous administration of VRCTC-310-ONCO in rabbits.
abstract: VRCTC-310-ONCO, an agent based on the snake phospholipase A2 (crotoxin), is currently under clinical development. After phase I study in patients by intramuscular administration, the interest of intravenous (IV) dosing arose. To evaluate IV administration of VRCTC-310-ONCO in rabbits, ten animals were subjected to surgical implant of fixed jugular catheter, by which they received daily IV doses of 0.03 mg/kg body weight of VRCTC-310-ONCO for 30 days (n = 8) or saline (n = 2). The procedure was well tolerated in all rabbits. One of the animals died after the sixth dose of VRCTC-310-ONCO with CNS involvement; two additional rabbits required dose-reduction. All other rabbits achieved 30 days of treatment and were sacrificed. All rabbits (even controls) developed lymphocytosis and mild anaemia, without changes in blood neutrophils. No changes were found in serum transaminases (GOT and GPT), cholesterol, triglycerides, and y-glutamyl transpeptidase. At necropsy, chronic granulation tissue was found surrounding the implant in all rabbits. VRCTC-3 10-ONCO-treated rabbits presented generalised and marked swelling of hepatocytes, with areas of cytoplasmic vacuolisation. No abnormalities were found in kidney, heart, lung, spleen, adrenal gland, uterus, testes and ovary. Additional studies with IV route for VRCTC-310-ONCO, including humans, are required to define its toxicity in the clinical setting.
authors.affiliation: Cáttedra de Microbiologia, Facultad de Ciencias Veterinarias, UNLP, La Plata, Argentina.
authors.forename: Nestor O
authors.initials: NO
authors.lastname: Stanchi
authors.forename: Daniel
authors.initials: D
authors.lastname: Arias
authors.forename: Pablo E
authors.initials: PE
authors.lastname: Martino
authors.forename: Roberto A
authors.initials: RA
authors.lastname: Diez
authors.forename: Luis A
authors.initials: LA
authors.lastname: Costa
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects / Q000473:pathology; D000818:Animals; D004179:Cobra Cardiotoxin Proteins / Q000008:administration & dosage* / Q000009:adverse effects* / Q000494:pharmacology; D003439:Crotoxin / Q000008:administration & dosage* / Q000009:adverse effects* / Q000494:pharmacology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D005260:Female; D006321:Heart / Q000187:drug effects; D022781:Hepatocytes / Q000187:drug effects / Q000473:pathology; D007262:Infusions, Intravenous / Q000009:adverse effects*; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008218:Lymphocytosis / Q000139:chemically induced; D008297:Male; D010053:Ovary / Q000187:drug effects / Q000473:pathology; D011817:Rabbits; D013737:Testis / Q000187:drug effects / Q000473:pathology; D013997:Time Factors; D014599:Uterus / Q000187:drug effects / Q000473:pathology
chemical_list: D004179:Cobra Cardiotoxin Proteins; D004338:Drug Combinations; C084936:cardiotoxin, crotoxin drug combination; D003439:Crotoxin